| Name | Loxapine succinate |
| Description | Loxapine succinate (Loxapac), a D2DR and D4DR inhibitor, is utilized in schizophrenia. |
| In vitro | In rats, subcutaneous injection of Loxapine (0.3 mg/kg) induces general stiffness. In the rat brain, administering Loxapine (5 mg/kg) does not alter dopamine receptor density, but it reduces serotonin receptor density. |
| In vivo | Loxapine effectively facilitates the binding of [3H]ketanserin to 5-HT2 receptors in both the human frontal cortex (ki=6.2 nM) and the bovine frontal cortex (ki=6.6 nM). Additionally, in LPS-activated mixed glial cells, loxapine at concentrations of 0.2 μM, 2 μM, and 20 μM, successfully reduces the secretion of IL-1β and IL-2. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | Ethanol : 2 mg/mL (4.49 mM), Sonication is recommended.
10% DMSO+40% PEG300+5% Tween 80+45% Saline : 3.3 mg/mL (7.4 mM), Sonication is recommended.
DMSO : 82 mg/mL (183.9 mM), Sonication is recommended.
|
| Keywords | Loxapine | IL-2 | DopamineReceptor | Dopamine Receptor | D4 | D2 | antipsychotics | 5HTReceptor | 5-HT2 (human) | 5-HT2 (bovine) | 5-HT Receptor | 5HT Receptor |
| Inhibitors Related | Trifluoperazine dihydrochloride | Alverine citrate | Dapoxetine hydrochloride | Cefaclor monohydrate | Clozapine N-Oxide | Octopamine hydrochloride | 1,8-Cineole | L-DOPA | Creatine | Oxolinic acid | Trazodone hydrochloride | Mianserin hydrochloride |
| Related Compound Libraries | Failed Clinical Trials Compound Library | Pain-Related Compound Library | Anti-Neurodegenerative Disease Compound Library | Membrane Protein-targeted Compound Library | Anti-Cancer Clinical Compound Library | Anti-Viral Compound Library | Drug Repurposing Compound Library | Inhibitor Library | Anti-Cancer Approved Drug Library | FDA-Approved Drug Library | Bioactive Compounds Library Max | GPCR Compound Library |
United States
